Verified employee & interview reviews

Cipla Reviews

Mumbai, Maharashtra

—/ 5

0 reviews

Cipla Limited is a prominent Indian multinational pharmaceutical company headquartered in Mumbai, India. Established on August 17, 1935, by the visionary scientist and entrepreneur Khwaja Abdul Hamied under the name "The Chemical, Industrial and Pharmaceutical Laboratories," the company was officially opened for business in September 1937. It underwent a strategic rebranding in July 1984, shortening its name to its current, globally recognized form. Since its inception, Cipla has been built on the core guiding purpose of "Caring for Life," dedicating its operations to ensuring access to quality and affordable medicines across the globe. Today, it stands as the third-largest drug producer in India and holds a dominant leadership position in the Indian pharmaceutical market. The core operations of Cipla are structurally divided into major strategic business segments, primarily focusing on Pharmaceuticals—which encompasses active pharmaceutical ingredients (APIs), generic medicines, complex generics, and formulations—and New Ventures, which includes its rapid expansion into consumer healthcare, digital therapeutics, and biosimilars. Globally, the company has extended its operational footprint to over 74 markets, providing a vast portfolio of more than 1,500 products across 65 diverse therapeutic categories, delivered in over 50 distinct dosage forms. Cipla maintains a deeply integrated global manufacturing and R&D infrastructure, boasting 47 state-of-the-art manufacturing facilities across the world alongside multiple cutting-edge research centers. Its manufacturing capabilities are certified by premier global health bodies, including the US FDA, WHO-Geneva, MHRA-UK, and TGA-Australia. Financially, Cipla is a publicly traded entity listed on both the National Stock Exchange (NSE) and the Bombay Stock Exchange (BSE) under the ticker CIPLA, and it constitutes a key component of the benchmark NSE NIFTY 50 index. Reflecting robust financial performance and steady growth, the company reported a consolidated revenue from operations of INR 27,548 crore (approximately USD 2.9 billion) and a net income of INR 5,273 crore (approximately USD 550 million) for the fiscal year ending March 31, 2025. This growth is historically anchored by high-margin chronic therapies, which account for over 60% of its branded prescription sales, notably in respiratory care, cardiovascular diseases, and central nervous system treatments. The company is also globally celebrated as the world's largest manufacturer of antiretroviral drugs, a legacy highlighted by its paradigm-shifting 2001 initiative that supplied a triple anti-retroviral therapy in Africa for less than a dollar a day. Under the ongoing leadership of Non-Executive Chairman Dr. Y.K. Hamied and a dedicated global workforce exceeding 27,000 employees, Cipla continues to heavily invest in sustainability and innovation, committing to a comprehensive Net Zero framework by 2050 while actively advancing healthcare from illness to wellness.